In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards’ percutaneous valve

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' "single largest investment increase" in the near term is to accelerate the European launch of its Sapien transcatheter heart valve, says CEO Michael Mussallem July 23 during the firm's 2007 second quarter earnings call. Edwards anticipates gaining CE mark for the device in time for year-end introduction. Competitor CoreValve (ReValving) got European approval in May. Edwards hopes to launch Sapien in the United States by 2010 (1"The Gray Sheet" March 26, 2007, p. 10). The company is also reinforcing its U.S. heart valve sales force in anticipation of FDA-approval of the Magna mitral tissue valve this year. But with timing of the Magna approval uncertain, the company is advising that its full year 2007 revenues will be on the low end of previous guidance of $1.07 billion to $1.11 billion, with heart valve sales in the second half of 2007 between $250 million and $260 million...

You may also be interested in...

Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve

Edwards Lifesciences will soon begin a 600-patient U.S. pivotal clinical trial for its Sapien transcatheter aortic replacement heart valve at Columbia University Medical Center and the Cleveland Clinic, the company says

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts